Matrix metalloproteinases and their endogenous inhibitors

Angiogenesis: An Integrative Approach From Science to Medicine

Volumn , Issue , 2008, Pages 55-62

  Guedez, Liliana ^a   Stetler Stevenson, William G ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

extracellular matrix; matrix metalloproteinase; protease; tissue inhibitor of metalloproteinase

Indexed keywords

EID: 84879187687     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-71518-6_5     Document Type: Chapter

References (83)

1. Bhowmick NA, Neilson EG, Moses HL: Stromal fibroblasts in cancer initiation and progression. Nature 2004;432:332-337.
2. Bissell MJ, Kenny PA, Radisky DC: Microenvironmental regulators of tissue structure and function also regulate tumor induction and progression: the role of extracellular matrix and its degrading enzymes. Cold Spring Harbor Symposia on Quantitative Biology 2005;70:343-356.
3. Gupta GP, Massague J: Cancer metastasis: building a framework. Cell 2006;127:679-695.
4. Gupta GP, Minn AJ, Kang Y, Siegel PM, Serganova I, Cordon-Cardo C, Olshen AB, Gerald WL, Massague J: Identifying site-specific metastasis genes and functions. Cold Spring Harbor Symposia on Quantitative Biology 2005;70:149-158.
5. Kalluri R: Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer 2003;3:422-433.
6. Carmeliet P: Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000;6:389-395.
7. Grunewald M, Avraham I, Dor Y, Bachar-Lustig E, Itin A, Jung S, Chimenti S, Landsman L, Abramovitch R, Keshet E: VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells.[see comment][erratum appears in Cell. 2006 Aug 25;126(4):811
8. Note: Yung, Steffen [corrected to Jung, Steffen]. Cell 2006;124:175-189.
9. Stetler-Stevenson WG: Matrix metalloproteinases in angiogen-esis: a moving target for therapeutic intervention. J Clin Invest 1999;103:1237-1241.
10. Nagase H, Visse R, Murphy G: Structure and function of matrix metalloproteinases and TIMPs. Cardiovascular Research 2006;69:562-573.
11. Visse R, Nagase H: Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003;92:827-839.
12. Fedarko NS, Jain A, Karadag A, Fisher LW: Three small inte-grin binding ligand N-linked glycoproteins (SIBLINGs) bind and activate specific matrix metalloproteinases. FASEB Journal 2004;18:734-736.
13. Roy R, Zhang B, Moses MA: Making the cut: protease-mediated regulation of angiogenesis. Exp Cell Res 2006;312:608-622.
14. Brew K, Dinakarpandian D, Nagase H: Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 2000;1477:267-283.
15. Chirco R, Liu XW, Jung KK, Kim HR: Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev 2006;25:99-113.
16. Jiang Y, Goldberg ID, Shi YE: Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 2002;21:2245-2252.
17. Lambert E, Dasse E, Haye B, Petitfrere E: TIMPs as multifacial proteins. Crit Rev Oncol Hematol 2004;49:187-198.
18. Gomis-Rüth FX, Maskos K, Betz M, Bergner A, Huber R, Suzuki K, Yoshida N, Nagase H, Brew K, Bourenkov G, Bartunik H, Bode W: Mechanism of inhibition of the human matrix metalloprotein-ase stromelysin-1 by TIMP-1. Nature 1997;Vol 389.
19. Fernandez CA, Moses MA: Modulation of angiogenesis by tissue inhibitor of metalloproteinase-4. Biochem Biophys Res Commun 2006;345:523-529.
20. Noda M, Oh J, Takahashi R, Kondo S, Kitayama H, Takahashi C: RECK: a novel suppressor of malignancy linking oncogenic signaling to extracellular matrix remodeling. Cancer Metastasis Rev 2003;22:167-175.
21. Oh J, Takahashi R, Kondo S, Mizoguchi A, Adachi E, Sasahara RM, Nishimura S, Imamura Y, Kitayama H, Alexander DB, Ide C, Horan TP, Arakawa T, Yoshida H, Nishikawa S, Itoh Y, Seiki M, Itohara S, Takahashi C, Noda M: The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell 2001;107:789-800.
22. Cornelius LA, Nehring LC, Roby JD, Parks WC, Welgus HG: Human dermal microvascular endothelial cells produce matrix metalloproteinases in response to angiogenic factors and migration. J Invest Dermatol 1995;105:170-176.
23. Haas TL: Endothelial cell regulation of matrix metalloprotein-ases. Can J Physiol Pharmacol 2005;83:1-7.
24. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D: Matrix metalloproteinase-9 triggers the angiogenic switch during carci-nogenesis. Nat Cell Biol 2000;2:737-744.
25. Chantrain CF, Shimada H, Jodele S, Groshen S, Ye W, Shalinsky DR, Werb Z, Coussens LM, DeClerck YA: Stromal matrix metallo-proteinase-9 regulates the vascular architecture in neuroblastoma by promoting pericyte recruitment. Cancer Res 2004;64:1675-1686.
26. Itoh T, Tanioka M, Yoshida H, Yoshioka T, Nishimoto H, Itohara S: Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res 1998;58:1048-1051.
27. Guedez L, Rivera AM, Salloum R, Miller ML, Diegmueller JJ, Bungay PM, Stetler-Stevenson WG: Quantitative assessment of angiogenic responses by the directed in vivo angiogenesis assay. Am J Pathol 2003;162:1431-1439.
28. Davis GE, Senger DR: Endothelial extracellular matrix: biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization. Circ Res 2005;97:1093-1107.
29. Hornebeck W, Emonard H, Monboisse JC, Bellon G: Matrix-directed regulation of pericellular proteolysis and tumor progression. Semin Cancer Biol 2002;12:231-241.
30. van Hinsbergh VW, Engelse MA, Quax PH: Pericellular proteases in angiogenesis and vasculogenesis. Arterioscler Thromb Vasc Biol 2006;26:716-728.
31. Chang C, Werb Z: The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol 2001;11:S37-43.
32. Masson V, de la Ballina LR, Munaut C, Wielockx B, Jost M, Maillard C, Blacher S, Bajou K, Itoh T, Itohara S, Werb Z, Libert C, Foidart JM, Noel A: Contribution of host MMP-2 and MMP-9 to promote tumor vascularization and invasion of malignant kerati-nocytes. Faseb J 2005;19:234-236.
33. Zucker S, Mirza H, Conner CE, Lorenz AF, Drews MH, Bahou WF, Jesty J: Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: conversion of prothrombin to thrombin results in progelatinase A activation and cell proliferation. Int J Cancer 1998;75:780-786.
34. Sounni NE, Noel A: Membrane type-matrix metalloproteinases and tumor progression. Biochimie 2005;87:329-342.
35. Chun TH, Sabeh F, Ota I, Murphy H, McDonagh KT, Holmbeck K, Birkedal-Hansen H, Allen ED, Weiss SJ: MT1-MMP-dependent neovessel formation within the confines of the three-dimensional extracellular matrix. J Cell Biol 2004;167:757-767.
36. Itoh Y, Seiki M: MT1-MMP: a potent modifier of pericellular microenvironment. J Cell Physiol 2006;206:1-8.
37. Holmbeck K, Bianco P, Birkedal-Hansen H: MT1-mmp: a collagenase essential for tumor cell invasive growth. Cancer Cell 2003;4:83-84.
38. Zhang W, Matrisian LM, Holmbeck K, Vick CC, Rosenthal EL: Fibroblast-derived MT1-MMP promotes tumor progression in vitro and in vivo. BMC Cancer 2006;6:52.
39. Collen A, Hanemaaijer R, Lupu F, Quax PH, van Lent N, Grimbergen J, Peters E, Koolwijk P, van Hinsbergh VW: Membrane-type matrix metalloproteinase-mediated angiogenesis in a fibrin-collagen matrix. Blood 2003;101:1810-1817.
40. Koike T, Vernon RB, Hamner MA, Sadoun E, Reed MJ: MT1-MMP, but not secreted MMPs, influences the migration of human microvascular endothelial cells in 3-dimensional collagen gels. J Cell Biochem 2002;86:748-758.
41. Sounni NE, Janssen M, Foidart JM, Noel A: Membrane type-1 matrix metalloproteinase and TIMP-2 in tumor angiogenesis. Matrix Biol 2003;22:55-61.
42. Lambert V, Wielockx B, Munaut C, Galopin C, Jost M, Itoh T, Werb Z, Baker A, Libert C, Krell HW, Foidart JM, Noel A, Rakic JM: MMP-2 and MMP-9 synergize in promoting choroidal neo-vascularization. Faseb J 2003;17:2290-2292.
43. Langlois S, Di Tomasso G, Boivin D, Roghi C, Murphy G, Gingras D, Beliveau R: Membrane type 1-matrix metalloproteinase induces endothelial cell morphogenic differentiation by a caspase-depen-dent mechanism. Exp Cell Res 2005;307:452-464.
44. Nabha SM, Bonfil RD, Yamamoto HA, Belizi A, Wiesner C, Dong Z, Cher ML: Host matrix metalloproteinase-9 contributes to tumor vascularization without affecting tumor growth in a model of prostate cancer bone metastasis. Clin Exp Metastasis 2006.
45. Li A, Dubey S, Varney ML, Dave BJ, Singh RK: IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol 2003;170:3369-3376.
46. Park H Y, Kwon HM, Lim HJ, Hong BK, Lee JY, Park BE, Jang Y, Cho S Y, Kim HS: Potential role of leptin in angiogenesis: leptin induces endothelial cell proliferation and expression of matrix metalloproteinases in vivo and in vitro. Exp Mol Med 2001;33:95-102.
47. Yu Q, Stamenkovic I: Cell surface-localized matrix metallopro-teinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 2000;14:163-176.
48. Hiratsuka S, Nakamura K, Iwai S, Murakami M, Itoh T, Kijima H, Shipley JM, Senior RM, Shibuya M: MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2002;2:289-300.
49. Annes JP, Munger JS, Rifkin DB: Making sense of latent TGF-beta activation. J Cell Sci 2003;116.
50. Levi E, Fridman R, Miao HQ, Ma YS, Yayon A, Vlodavsky I: Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1. Proc Natl Acad Sci USA 1996;93:7069-7074.
51. Paduch R, Walter-Croneck A, Zdzisinska B, Szuster-Ciesielska A, Kandefer-Szerszen M: Role of reactive oxygen species (ROS), metalloproteinase-2 (MMP-2) and interleukin-6 (IL-6) in direct interactions between tumour cell spheroids and endothelial cell monolayer. Cell Biol Int 2005;29:497-505.
52. Smith MM, Shi L, Navre M: Rapid identification of highly active and selective substrates for stromelysin and matrilysin using bacteriophage peptide display libraries. J Biol Chem 1995;270: 6440-6449.
53. Haque NS, Fallon JT, Pan JJ, Taubman MB, Harpel PC: Che-mokine receptor-8 (CCR8) mediates human vascular smooth muscle cell chemotaxis and metalloproteinase-2 secretion. Blood 2004;103:1296-1304.
54. Rundhaug JE: Matrix metalloproteinases and angiogenesis. J Cell Mol Med 2005;9:267-285.
55. Caudroy S, Polette M, Nawrocki-Raby B, Cao J, Toole BP, Zucker S, Birembaut P: EMMPRIN-mediated MMP regulation in tumor and endothelial cells. Clin Exp Metastasis 2002;19: 697-702.
56. Burbridge MF, Coge F, Galizzi JP, Boutin JA, West DC, Tucker GC: The role of the matrix metalloproteinases during in vitro vessel formation. Angiogenesis 2002;5:215-226.
57. Kondo M, Asai T, Katanasaka Y, Sadzuka Y, Tsukada H, Ogino K, Taki T, Baba K, Oku N: Anti-neovascular therapy by liposomal drug targeted to membrane type-1 matrix metalloproteinase. Int J Cancer 2004;108:301-306.
58. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-285.
59. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J: Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315-328.
60. O'Reilly MS, Wiederschain D, Stetler-Stevenson WG, Folkman J, Moses MA: Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance. J Biol Chem 1999;274:29568-29571.
61. Patterson BC, Sang QA: Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9). J Biol Chem 1997;272:28823-28825.
62. Kalluri R: Discovery of type IV collagen non-collagenous domains as novel integrin ligands and endogenous inhibitors of angiogenesis. Cold Spring Harbor Symposia on Quantitative Biology 2002;67:255-266.
63. Borza CM, Pozzi A, Borza DB, Pedchenko V, Hellmark T, Hudson BG, Zent R: Integrin alpha3beta1, a novel receptor for alpha3(IV) noncollagenous domain and a trans-dominant Inhibitor for integrin alphavbeta3. J Biol Chem 2006;281: 20932-20939.
64. Rodrigues RG, Guo N, Zhou L, Sipes JM, Williams SB, Templeton NS, Gralnick HR, Roberts DD: Conformational regulation of the fibronectin binding and alpha 3beta 1 integrin-mediated adhesive activities of thrombospondin-1. J Biol Chem 2001;276:27913-27922.
65. Wang H, Fu W, Im JH, Zhou Z, Santoro SA, Iyer V, DiPersio CM, Yu QC, Quaranta V, Al-Mehdi A, Muschel RJ: Tumor cell alpha3beta1 integrin and vascular laminin-5 mediate pulmonary arrest and metastasis. J Cell Biol 2004;164:935-941.
66. Chang S, Young BD, Li S, Qi X, Richardson JA, Olson EN: Histone deacetylase 7 maintains vascular integrity by repressing matrix metalloproteinase 10. Cell 2006;126:321-334.
67. Qi JH, Ebrahem Q, Moore N, Murphy G, Claesson-Welsh L, Bond M, Baker A, Anand-Apte B: A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angio-genesis by blockage of VEGF binding to VEGF receptor-2. Nature Med 2003;9:407-415.
68. Saunders WB, Bohnsack BL, Faske JB, Anthis NJ, Bayless KJ, Hirschi KK, Davis GE: Coregulation of vascular tube stabilization by endothelial cell TIMP-2 and pericyte TIMP-3. J Cell Biol 2006;175:179-191.
69. Cruz-Munoz W, Kim I, Khokha R: TIMP-3 deficiency in the host, but not in the tumor, enhances tumor growth and angiogenesis. Oncogene 2006;25:650-655.
70. Nisato RE, Hosseini G, Sirrenberg C, Butler GS, Crabbe T, Docherty AJ, Wiesner M, Murphy G, Overall CM, Goodman SL, Pepper MS: Dissecting the role of matrix metalloprotein-ases (MMP) and integrin alpha(v)beta3 in angiogenesis in vitro: absence of hemopexin C domain bioactivity, but membrane-Type 1-MMP and alpha(v)beta3 are critical. Cancer Res 2005;65:9377-9387.
71. Jones GC, Riley GP: ADAMTS proteinases: a multi-domain, multi-functional family with roles in extracellular matrix turnover and arthritis. Arthritis Res Ther 2005;7:160-169.
72. Moses MA, Sudhalter J, Langer R: Identification of an inhibitor of neovascularization from cartilage. Science 1990;248: 1408-1410.
73. Murphy AN, Unsworth EJ, Stetler-Stevenson WG: Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation. J Cell Physiol 1993;157:351-358.
74. Fernandez CA, Butterfield C, Jackson G, Moses MA: Structural and functional uncoupling of the enzymatic and angiogenic inhibitory activities of tissue inhibitor of metalloproteinase-2 (TIMP-2): loop 6 is a novel angiogenesis inhibitor. J Biol Chem 2003;278:40989-40995.
75. Seo DW, Li H, Guedez L, Wingfield PT, Diaz T, Salloum R, Wei BY, Stetler-Stevenson WG: TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism. Cell 2003;114:171-180.
76. Perez-Martinez L, Jaworski DM: Tissue inhibitor of metallopro-teinase-2 promotes neuronal differentiation by acting as an anti-mitogenic signal. J Neurosci 2005;25:4917-4929.
77. Seo DW, Li H, Qu CK, Oh J, Kim YS, Diaz T, Wei B, Han JW, Stetler-Stevenson WG: Shp-1 mediates the antiproliferative activity of tissue inhibitor of metalloproteinase-2 in human microvascular endothelial cells. J Biol Chem 2006;281: 3711-3721.
78. Akahane T, Akahane M, Shah A, Connor CM, Thorgeirsson UP: TIMP-1 inhibits microvascular endothelial cell migration by MMP-dependent and MMP-independent mechanisms. Exp Cell Res 2004;301:158-167.
79. Guedez L, McMarlin AJ, Kingma DW, Bennett TA, StetlerStevenson M, Stetler-Stevenson WG: Tissue inhibitor of metal-loproteinase-1 alters the tumorigenicity of Burkitt's lymphoma via divergent effects on tumor growth and angiogenesis.[see comment]. Am J Pathol 2001;158:1207-1215.
80. Ikenaka Y, Yoshiji H, Kuriyama S, Yoshii J, Noguchi R, Tsujinoue H, Yanase K, Namisaki T, Imazu H, Masaki T, Fukui H: Tissue inhibitor of metalloproteinases-1 (TIMP-1) inhibits tumor growth and angiogenesis in the TIMP-1 transgenic mouse model. Int J Cancer 2003;105:340-346.
81. Johnson MD, Choi H-R, Chesler L, Tsao-Wu G, Bouck N, Polverini PJ: Inhibition of Angiogenesis by Tissue Inhibitor of Metalloproteinase. J Cell Physiol 1994;160:194-202.
82. Thorgeirsson UP, Yoshiji H, Sinha CC, Gomez DE: Breast cancer; Tumor neovasculature and the effect of tissue inhibitor of metalloproteinases-1 (TIMP-1) on angiogenesis. In Vivo 1996;10:137-144.
83. Yamada E, Tobe T, Yamada H, Okamoto N, Zack DJ, Werb Z, Soloway PD, Campochiaro PA: TIMP-1 promotes VEGF-induced neovascularization in the retina. Histol Histopathol 2001;16:87-97.